ArticleJACC. Asia2025
1-Year Outcomes of PT-Valve for Pulmonary Regurgitation in Native Outflow Tract.
Article in JACC. Asia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Bench to Bedside in China: Domestic Devices and Experience in Structural Interventions.JACC. Case reports · 2025Article
- A New Option for Self-Expanding Transcatheter Pulmonary Valve.JACC. Asia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere pulmonary regurgitation (PR) in patients with postoperative congenital heart disease is often accompanied by extensive variability of right ventricular outflow tract (RVOT) anatomy, which limited the wide application of existing transcatheter pulmonary valves device.
objectivesThis study sought to evaluate 1-year safety and efficacy of the PT-Valve in the treatment of PR patients presenting with native RVOT from a multicenter, single-arm clinical trial.
methodsWe enrolled 130 patients of moderate or greater PR. One-year clinical outcomes are reported.
resultsWithin the cohort (mean age 30 ± 16 years; 52% men), 124 (95%) were diagnosed with tetralogy of Fallot. The procedure success rate was 98.5%. Early explants occurred to 2 device malpositions and 1 pulmonary branch obstruction. At 1 year, there were no procedure- or device-related mortality. Device-related adverse events included 2 arrhythmias, 1 pulmonary thromboembolism, 2 endocarditis, and 1 vascular access complication. Echocardiography examinations showed that 125 (99%) patients had none/trace and mild PR, and no greater than mild paravalvular leak at 1-year visit. The mean peak pulmonary gradient was 20.0 ± 17.4 mm Hg and 16.0 ± 7.8 mm Hg at baseline and 1 year after implantation, respectively. The right ventricular end-diastolic volume index was reduced from 176.3 ± 28.4 mL/m
conclusionsThe PT-Valve demonstrated a high success rate of implantation and favorable safety and efficacy in the treatment of PR through 1 year. This device is anatomically suitable for more than 90% of PR patients with native RVOT. (Prospective, Single Arm, Multi-Center Clinical Study on the Safety And Efficacy of the Sterile Transcatheter Pulmonary Valve and Delivery System; ChiCTR2100043367).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.